• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2.一名难治性霍奇金淋巴瘤患者使用帕博利珠单抗治疗期间感染新型冠状病毒 2 的病例结果。
Br J Haematol. 2020 Jul;190(1):e1-e3. doi: 10.1111/bjh.16798. Epub 2020 May 25.
2
What to Do With Deauville 3 Interim Positron Emission Tomography/Computed Tomography Response in a Young Woman With Classic Unfavorable Hodgkin's Lymphoma: To Irradiate or Not to Irradiate?一名患有典型不良霍奇金淋巴瘤的年轻女性出现Deauville 3期中期正电子发射断层扫描/计算机断层扫描反应该如何处理：是否进行放疗？
Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):13-14. doi: 10.1016/j.ijrobp.2018.02.162.
3
[Treatment strategy of Hodgkin lymphoma].[霍奇金淋巴瘤的治疗策略]
Rinsho Ketsueki. 2014 Oct;55(10):1941-51.
4
Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?中期正电子发射断层扫描（PET）能否提高晚期霍奇金淋巴瘤患者使用阿霉素、博来霉素、长春新碱和达卡巴嗪（ABVD）化疗方案的价值？
Ann Oncol. 2015 Jun;26(6):1045-1047. doi: 10.1093/annonc/mdv160.
5
Treatment of advanced stage Hodgkin lymphoma--it's all about risk-benefit.晚期霍奇金淋巴瘤的治疗——一切都关乎风险与获益。
Br J Haematol. 2012 Oct;159(1):113-5. doi: 10.1111/j.1365-2141.2012.09234.x. Epub 2012 Jul 24.
6
Chemotherapy for Hodgkin's disease.霍奇金病的化疗
N Engl J Med. 2003 Sep 18;349(12):1186-7; author reply 1186-7. doi: 10.1056/NEJM200309183491217.
7
Small lymphocytic lymphoma secondary to young patient with a history of classical Hodgkin Lymphoma.继发于有经典型霍奇金淋巴瘤病史的年轻患者的小淋巴细胞淋巴瘤。
Int J Lab Hematol. 2022 Feb;44(1):31-33. doi: 10.1111/ijlh.13642. Epub 2021 Jul 3.
8
Balancing risk and benefit in early-stage classical Hodgkin lymphoma.平衡早期经典型霍奇金淋巴瘤的风险和获益。
Blood. 2018 Apr 12;131(15):1666-1678. doi: 10.1182/blood-2017-10-772665. Epub 2018 Mar 2.
9
Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma.当代治疗经典疾病的选择：晚期霍奇金淋巴瘤。
Crit Rev Oncol Hematol. 2020 Apr;148:102897. doi: 10.1016/j.critrevonc.2020.102897. Epub 2020 Feb 13.
10
Treatment of Hodgkin lymphoma: a 50-year perspective.霍奇金淋巴瘤的治疗：50年回顾
J Clin Oncol. 2014 Jan 20;32(3):163-8. doi: 10.1200/JCO.2013.53.1194.

引用本文的文献

1
Immune checkpoint inhibitors in cancer patients with COVID-19.新冠病毒病（COVID-19）癌症患者中的免疫检查点抑制剂
Open Life Sci. 2023 Jul 7;18(1):20220641. doi: 10.1515/biol-2022-0641. eCollection 2023.
2
SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.癌症患者接受免疫检查点抑制剂治疗时的 SARS-CoV-2 感染和 COVID-19 疫苗接种。
Cell Death Dis. 2023 Jun 30;14(6):390. doi: 10.1038/s41419-023-05922-w.
3
Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.COVID-19 合并血液系统恶性肿瘤患者的合并症和死亡率：系统评价和荟萃分析。
J Clin Lab Anal. 2022 May;36(5):e24387. doi: 10.1002/jcla.24387. Epub 2022 Apr 6.
4
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review.淋巴瘤患者中的新型冠状病毒肺炎（严重急性呼吸综合征冠状病毒2感染）：综述
World J Virol. 2021 Nov 25;10(6):312-325. doi: 10.5501/wjv.v10.i6.312.
5
Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas.SARS-CoV-2 导致孤立性淋巴瘤病例中罕见抗肿瘤免疫反应的潜在分子机制。
Viruses. 2021 Sep 25;13(10):1927. doi: 10.3390/v13101927.
6
Impact of COVID-19 in patients with lymphoid malignancies.新型冠状病毒肺炎对淋巴系统恶性肿瘤患者的影响。
World J Virol. 2021 May 25;10(3):97-110. doi: 10.5501/wjv.v10.i3.97.
7
Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era.COVID-19 大流行期间肿瘤学中免疫检查点抑制剂管理的利弊
Cancers (Basel). 2021 Apr 15;13(8):1906. doi: 10.3390/cancers13081906.
8
Weathering the storm: COVID-19 infection in patients with hematological malignancies.安然度过风暴：血液系统恶性肿瘤患者的 COVID-19 感染。
J Zhejiang Univ Sci B. 2020;21(12):921-939. doi: 10.1631/jzus.B2000423.
9
Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.病例报告：一名复发/难治性霍奇金淋巴瘤患者的重症新型冠状病毒肺炎
Front Oncol. 2021 Mar 18;11:601709. doi: 10.3389/fonc.2021.601709. eCollection 2021.
10
COVID-19 in Immunocompromised Hosts: What We Know So Far.免疫功能低下宿主中的 COVID-19：目前我们已知的情况。
Clin Infect Dis. 2021 Jan 27;72(2):340-350. doi: 10.1093/cid/ciaa863.

本文引用的文献

1
Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.关于新型冠状病毒肺炎和使用免疫检查点抑制剂进行抗癌治疗的争议。
Immunotherapy. 2020 Apr;12(5):269-273. doi: 10.2217/imt-2020-0067. Epub 2020 Mar 26.
2
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.SARS-CoV-2 在武汉一家三级医院癌症患者中的传播。
JAMA Oncol. 2020 Jul 1;6(7):1108-1110. doi: 10.1001/jamaoncol.2020.0980.
3
Clinical progression of patients with COVID-19 in Shanghai, China.中国上海 COVID-19 患者的临床进展。
J Infect. 2020 May;80(5):e1-e6. doi: 10.1016/j.jinf.2020.03.004. Epub 2020 Mar 19.
4
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.免疫检查点抑制剂免疫相关不良事件的临床特征与治疗
Immune Netw. 2020 Feb 17;20(1):e9. doi: 10.4110/in.2020.20.e9. eCollection 2020 Feb.
5
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
6
Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients.癌症患者免疫检查点阻断期间流感感染与疫苗接种的免疫学见解
Immunotherapy. 2020 Feb;12(2):105-110. doi: 10.2217/imt-2019-0200. Epub 2020 Feb 12.
7
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.临床证据不支持使用皮质类固醇治疗2019新型冠状病毒肺炎肺损伤。
Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.
8
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.接受免疫检查点阻断治疗黑色素瘤患者的严重感染谱
Clin Infect Dis. 2016 Dec 1;63(11):1490-1493. doi: 10.1093/cid/ciw539. Epub 2016 Aug 7.

Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2.

作者信息

O'Kelly Brendan, McGettrick Padraig, Angelov Daniel, Fay Michael, McGinty Tara, Cotter Aoife G, Sheehan Gerard, Lambert John S

机构信息

Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin, Ireland.

Centre for Experimental Pathogen Host Research, University College Dublin, Dublin, Ireland.

出版信息

Br J Haematol. 2020 Jul;190(1):e1-e3. doi: 10.1111/bjh.16798. Epub 2020 May 25.

DOI:10.1111/bjh.16798
PMID:32379903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7267253/
Abstract
摘要